ClinicalTrials.gov
public full text
Public Domain
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
breast-cancercolon-cancerlung-cancerpancreatic-cancerprotocol-specificrectal-cancerunspecified-adult-solid-tumor
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer. Diagnostic procedures, such as copper Cu 64 anti-CEA monoclonal antibody M5A PET, may help find and diagnose CEA positive cancer that may not be detected by standard diagnostic methods.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning#1171866
- Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses#812851
- Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma#902235
- The Role of Ceus in the Characterization of Focal Liver Lesions Indeterminate to Second-level Methods#1087723
- Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT#1151449
Record · ID 1184453
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive